Approach

Summary

Licensing status

Publication and contact information

Markers

Markers of distinct sonic hedgehog homolog (SHH)-driven medulloblastomas

Mouse and sequencing studies suggest SHH-driven medulloblastomas in adults, children and infants are molecularly distinct from one another and should be treated using different protocols. Most adults but only about half of pediatric patients with SHH-driven medulloblastomas respond to smoothened (SMO) inhibitors. In SHH-driven medulloblastoma tumor samples from 50 adults, 33 children over 3 years old and 50 infants, sequencing showed that SMO mutations were enriched in adults, suppressor of fused homolog (SUFU) mutations were found almost exclusively in infants and amplifications in both v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC) and glioma-associated oncogene homolog 2 zinc finger protein (GLI2) plus p53 mutations were enriched in children. In mouse xenograft models, SUFU-mutated and MYCN-amplified SHH-driven medulloblastomas showed resistance to the small molecule SMO inhibitor LDE225. Next steps could include developing a patient screening assay for the gene alterations.
Novartis AG has LDE225 in Phase III testing to treat basal cell carcinoma (BCC) and Phase I testing to treat other cancers.
Roche's Genentech Inc. unit markets the SMO inhibitor Erivedge vismodegib to treat BCC.
At least four other companies have SMO inhibitors in Phase III or earlier testing to treat various cancers.

SciBX 7(15); doi:10.1038/scibx.2014.444
Published online April 17, 2014

Patent and licensing status unavailable

Kool, M. et al. Cancer Cell; published online March 17, 2014;
doi:10.1016/j.ccr.2014.02.004
Contact: Marcel Kool, German Cancer Research Center, Heidelberg, Germany
e-mail:

m.kool@dkfz.de